Brasada Capital Management LP Invests $3.06 Million in Neogen Corporation $NEOG

Brasada Capital Management LP purchased a new stake in Neogen Corporation (NASDAQ:NEOG) in the second quarter, HoldingsChannel reports. The firm purchased 340,305 shares of the company’s stock, valued at approximately $3,059,000.

A number of other hedge funds have also modified their holdings of the company. AQR Capital Management LLC increased its stake in Neogen by 217.0% in the first quarter. AQR Capital Management LLC now owns 52,410 shares of the company’s stock valued at $443,000 after purchasing an additional 35,878 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Neogen by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 129,813 shares of the company’s stock worth $1,125,000 after purchasing an additional 5,638 shares in the last quarter. Jones Financial Companies Lllp boosted its position in shares of Neogen by 5,687.3% during the first quarter. Jones Financial Companies Lllp now owns 33,393 shares of the company’s stock worth $290,000 after purchasing an additional 32,816 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Neogen by 14.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,678,493 shares of the company’s stock valued at $14,553,000 after buying an additional 209,990 shares during the period. Finally, United Services Automobile Association acquired a new position in shares of Neogen in the 1st quarter valued at $112,000. 96.73% of the stock is currently owned by institutional investors and hedge funds.

More Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management, suggesting analysts see potential for improved execution and a stronger outlook under the company’s leadership changes. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several Neogen EPS forecasts: FY2027 estimates increased to $0.25 from $0.21, FY2028 to $0.29 from $0.28, and FY2029 was projected at $0.32. Quarterly estimates for Q2 and Q3 FY2027, Q4 FY2027 and Q3–Q4 FY2028 were also raised, signaling expectations for gradual earnings improvement. These forecasts are broadly in line with or above the current-year consensus of $0.25 EPS.
• Neutral Sentiment: Signal Proxy Intelligence recommended shareholders support all five proposals at Neogen’s annual meeting. The endorsement may reduce governance uncertainty, but it is unlikely to materially change near-term earnings or valuation. Signal Proxy Intelligence Recommends Full Support for All Five Items at Neogen Corporation Annual Meeting
• Neutral Sentiment: A Zacks comparison of Perrigo and Neogen framed the stocks as competing medical-products value investments. The article does not represent a specific change to Neogen’s rating or outlook. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Zacks lowered its Q1 FY2028 EPS forecast to $0.05 from $0.06, partially offsetting the broader upward revisions. The change suggests some unevenness in the pace of Neogen’s expected earnings recovery.

Wall Street Analyst Weigh In

Several analysts recently commented on NEOG shares. Weiss Ratings raised Neogen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th. Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Piper Sandler upgraded Neogen from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $13.00 to $14.00 in a report on Wednesday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Neogen Stock Performance

Shares of NEOG opened at $11.74 on Friday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.91 and a current ratio of 3.82. Neogen Corporation has a twelve month low of $4.90 and a twelve month high of $12.85. The firm’s 50 day moving average price is $10.42 and its two-hundred day moving average price is $9.85. The firm has a market cap of $2.56 billion, a P/E ratio of -391.33, a PEG ratio of 4.39 and a beta of 1.77.

Neogen (NASDAQ:NEOG) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.03. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The company had revenue of $225.30 million during the quarter, compared to the consensus estimate of $212.35 million. During the same quarter in the prior year, the firm earned ($2.82) earnings per share. The firm’s revenue was down .1% compared to the same quarter last year. On average, analysts forecast that Neogen Corporation will post 0.27 EPS for the current fiscal year.

Neogen Company Profile

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.